Table 1.
Characteristics of stent type and inflammatory response
| Stent name (manufacturer) | BMS | 1st DES | 2nd DES | BP-DES | BVS | ||
|---|---|---|---|---|---|---|---|
| Bx Velocity (Medtronic) | CYPHER (Johnson & Johnson) | TAXUS Express2 (Boston Scientific) | XIENCE V (Abbott Vascular) | RESOLUTE (Medtronic) | SYNERGY (Boston Scientific) | Absorb BVS (Abbott Vascular) | |
| Drug eluted | – | Sirolimus (1.4 µg/mm2) | Paclitaxel (1 µg/mm2) | Everolimus (1 µg/mm2) | Zotarolimus (1 µg/mm2) | Everolimus (1 µg/mm2) | Everolimus |
| Polymer type | – | PEVA and PBMA | SIBS | VDF-HFP and PBMA | C10, C19, and PVP | Bioresorbable PLGA (abluminal coating; bioresorption kinetics: 4 months) | PDLLA |
| Kinetic of drug elution | – | 80% within 30 days; remainder released by the end of 90 days | < 10% at 30 days; 90% remains sequestered within the polymer formulation without further measurable release | 80% within 30 days; remainder released by the end of 120 days | 70% within 30 days; remainder released by the end of 120 days | 50% within 2 months and w100% at 3 months | 80% of the drug is released in 28 days |
| Metal platform | SS | SS | SS | CoCr | CoCr | PtCr |
– (PLLA) |
| Strut thickness [µm) | 140 | 140 | 132 | 81 | 91 | 74 | 150 |
| Signs of inflammation | ++ | +++ | +++ | + | + | + | ++ |
PB-DES biodegradable polymer-based drug eluting stent, C10 polybutyl methacrylate, C19 polyhexyl methacrylate, polyvinyl acetate, CoCr cobalt chromium alloy, PBMA poly n-butyl methacrylate, PC phosphorylcholine, PEVA polyethylene-co-vinyl acetate, PtCr platinum chromium alloy, PVDF-HFP polyvinylidene fluoride co-hexafluoropropylene, PVP polyvinyl pyrrolidone, SIBS poly(styrene-b-isobutylene-b-styrene), SS stainless steel, PLGA poly(d,l-lactidecoglycolide acid), PDLLA poly-d,l-lactide